Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA

WASHINGTON , Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that NASDAQ halted trading of Vanda common stock this morning. The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration ( FDA ) meets today to review Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ ™ , for the treatment of Non-24-Hour Disorder in the totally blind. The Advisory Committee meeting is scheduled for 8:00 am ET . Vanda's HETLIOZ ™ NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014 . Investor Contact: Chad Rubin Vice President The Trout Group (646) 378-2947 [email protected] Media Contact: Laney Landsman Assistant Vice President Makovsky (212) 508-9643 [email protected] SOURCE Vanda Pharmaceuticals Inc. Investor Relations IR Home Stock Information Stock Quote Stock Chart SEC Filings Analyst Coverage Corporate Governance Highlights Management Board of Directors Committee Composition Guidelines VandaHotline Information Request E-mail Alerts Tools Print Page E-mail Page Home About Vanda Product Pipeline Partnering investor Relations News Careers Contact Us Copyright © 2005-2026 Vanda Pharmaceuticals Inc. | Live - Terms & Policy Terms & Conditions | Privacy Policy

The release as fetched from its publisher. vandapharma.com ↗